WO2018024034A1 - 环状RNA circ-NFATC3及其用途 - Google Patents

环状RNA circ-NFATC3及其用途 Download PDF

Info

Publication number
WO2018024034A1
WO2018024034A1 PCT/CN2017/087834 CN2017087834W WO2018024034A1 WO 2018024034 A1 WO2018024034 A1 WO 2018024034A1 CN 2017087834 W CN2017087834 W CN 2017087834W WO 2018024034 A1 WO2018024034 A1 WO 2018024034A1
Authority
WO
WIPO (PCT)
Prior art keywords
nfatc3
circ
gene
liver cancer
circular rna
Prior art date
Application number
PCT/CN2017/087834
Other languages
English (en)
French (fr)
Inventor
吴文哲
何重华
罗景燕
殷豪
杨畔
赖炳权
Original Assignee
广州永诺生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州永诺生物科技有限公司 filed Critical 广州永诺生物科技有限公司
Publication of WO2018024034A1 publication Critical patent/WO2018024034A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the invention belongs to the fields of molecular biology and oncology, and particularly relates to a circular RNA circ-NFATC3 and its use.
  • Hepatocellular carcinoma is one of the most common malignancies worldwide. About 740,000 patients worldwide are newly diagnosed with hepatocellular carcinoma each year, and about 690,000 patients die of liver cancer. Among them, China accounts for 55% of the new annual cases in the world, and it has become one of the regions with the highest incidence of liver cancer in the world.
  • AFP is the only serological marker widely accepted for the diagnosis or detection of liver cancer. Its sensitivity for diagnosing liver cancer can only reach about 50%. Many factors ultimately lead to more than 70% of patients. At the time of the first visit, he had advanced into the advanced stage of liver cancer, thus losing the opportunity for surgical radical treatment including surgical resection or liver transplantation. Therefore, in-depth study of the molecular mechanism of the occurrence and development of liver cancer, the development of new diagnostic markers and therapeutic targets have become the hotspots and key areas of current cancer research.
  • a circular RNA is a new member of the RNA family that differs from traditional linear RNA. It does not have a 5' end cap and a 3' terminal poly(A) tail, and forms a circular structure of non-coding RNA molecules by covalent bonds. .
  • circRNA has a closed loop structure, mainly produced by atypical variable shear processing, widely existed in various biological cells, has structural stability, is difficult to be degraded by RNase, has high expression abundance, and is well preserved between species. The expression has the characteristics of tissue and time-space specificity. These characteristics make circRNA have broad prospects in the development and application of new disease diagnosis and treatment methods.
  • Circ-NFATC3 (CircBase ID: hsa_Circ_0000711), whose location on the genome is: Chr16:68155889-68160513, the corresponding linear gene is NFATC3 (NM_173165), and the circularized sequence has 1298 bases, including the second and third exons of the NFATC3 gene.
  • Applicants have found that the RNA of NFATC3 gene in liver tissue is cyclized, and the expression of circular RNA circ-NFATC3 is significantly down-regulated in hepatocarcinoma. Over-expression of circ-NFATC3 inhibits proliferation, migration and invasion of hepatoma cells, suggesting circ- NFATC3 may become a new approach to the diagnosis and treatment of liver cancer.
  • the object of the present invention is to provide a diagnosis based on the expression of the circ-NFATC3 gene and its expression product in liver cancer according to the research on the expression of the circular RNA circ-NFATC3 in human liver cancer and its regulation on the biological function of liver cancer cells. The use of treatment.
  • the technical solution adopted by the present invention is: a circular RNA circ-NFATC3, and the nucleotide sequence of the gene of the circular RNA circ-NFATC3 is shown in SEQ ID NO: 1.
  • the structure of the circular RNA circ-NFATC3 is an end-to-end circular RNA structure formed by splicing after the nucleotide sequence shown in SEQ ID NO: 1.
  • the present invention also provides a pharmaceutical composition comprising the above cyclic RNA circ-NFATC3.
  • the present invention also provides a liver cancer diagnostic kit comprising a primer capable of amplifying the circular RNA circ-NFATC3 as described above.
  • the amplification primer is a primer pair consisting of the DNA sequence as shown in SEQ ID NO: 2 and SEQ ID NO: 3 or a DNA sequence as shown in SEQ ID NO: 4 and SEQ ID NO: 5. A set of primer pairs.
  • the present invention also provides the use of the above-mentioned circular RNA circ-NFATC3 in the preparation of a medicament for treating liver cancer.
  • the present invention also provides the use of the circ-NFATC3 gene as a target gene for preparing a medicament for treating liver cancer, wherein the nucleotide sequence of the circ-NFATC3 gene is as shown in SEQ ID NO: 1.
  • the present invention firstly confirms the objective existence of the circ-NFATC3 gene by designing specific circular RNA primers for RT-PCR, generation sequencing, and RNase degradation experiments;
  • the present invention detects the expression of circ-NFATC3 gene in liver cancer patients, and finds that its expression level is significantly reduced, and thus can be used as a diagnostic marker for liver cancer;
  • the in vitro cell functional study of the circ-NFATC3 gene was carried out by constructing the circ-NFATC3 gene sequence into the LVminiCirc lentiviral vector to construct a Huh7 stable hepatoma cell line overexpressing the circ-NFATC3 gene.
  • the proliferation rate, cell migration rate and cell invasion ability of liver cancer cells overexpressing circ-NFATC3 gene were significantly lower than those of control liver cancer cells transfected with empty vector.
  • the circ-NFATC3 gene and its expression product can be used in the preparation of a medicament for treating liver cancer.
  • the circ-NFATC3 gene and its expression products serve as markers for the diagnosis of liver cancer, making the diagnosis of liver cancer more accurate and rapid.
  • As a target gene for the preparation of liver cancer drugs it provides a new therapeutic target and therapeutic approach for the treatment of liver cancer.
  • Example 1 is an agarose gel electrophoresis pattern of the expression product of the circ-NFATC3 gene in Example 1 of the present invention
  • Fig. 2 is a bar graph showing the effect of RNaseR on circ-NFATC3 and GAPDH in Example 2 of the present invention.
  • Example 3 is a comparison diagram of the results of detecting circ-NFATC3 expression in liver cancer tissues by QPCR in Example 2 of the present invention
  • Example 4 is a fluorescence micrograph and a result of expression of a stable cell strain constructed in Example 3 of the present invention
  • FIG. 5 is a schematic diagram showing the cell proliferation curve after specifically expressing the circ-NFATC3 gene in the liver cancer cell Huh7 in Example 4, wherein the abscissa is the number of days, and the ordinate is the 490 nm absorbance detected by the microplate reader;
  • FIG. 6 is a schematic diagram showing the results of cell migration experiments in which the circ-NFATC3 gene was specifically overexpressed in the liver cancer cell Huh7 in Example 5, wherein the abscissa is the name of the treatment group and the ordinate is the number of cells undergoing migration.
  • FIG. 7 is a schematic diagram showing the results of cell invasion assays in which the circ-NFATC3 gene was specifically overexpressed in the liver cancer cell Huh7 in Example 6 of the present invention, wherein the abscissa is the name of the treatment group and the ordinate is the number of cells invading.
  • the invention firstly designs a circular RNA of the NFATC3 gene by designing a specific primer capable of amplifying the circular RNA, and then performs an RNaseR degradation experiment, and determines that the expression of the NFATC3 gene is composed of 1298 nucleotides, A circular RNA molecule that closes a circular structure.
  • the present invention detects the difference in expression of the circ-NFATC3 gene in a liver cancer sample by using a real-time quantitative PCR method, and the results show that the expression level of the circ-NFATC3 gene in liver cancer tissues is significantly lower than that in the adjacent tissues. Therefore, a kit for detecting changes in expression of the gene can be prepared for diagnosis of liver cancer.
  • the techniques involved in the present invention are all conventional techniques for molecular cloning, and the enzymes, primers, reagents and reaction conditions involved can be reasonably selected according to the experience of those skilled in the art, and the reagent consumables are involved.
  • Commercially available general products, the detection means and instruments involved therein are also well known and well-understood by those skilled in the art.
  • Example 1 RT-PCR reaction was used to detect the expression of the circ-NFATC3 gene in liver cancer tissues.
  • Tissue treatment Add about 10 mg of tissue to 1 ml of Trizol, homogenize with a homogenizer; centrifuge for 15 minutes, 12000 g, and take the supernatant.
  • the lysate is divided into three layers: the upper layer is the aqueous phase of the RNA; The middle layer is DNA, lipids, etc.; the lower layer is cell residue, protein, polysaccharide, and the like.
  • RNA primers were reverse primers, and a pair of forward primers were designed as controls.
  • a set of gDNA template controls was established by RT-PCR, which confirmed that the circRNAs were derived from post-transcriptional cleavage rather than mutations such as gene fusion.
  • the linear gene GAPDH was also tested as a negative control.
  • the primers used are listed below:
  • PCR GAPDH was used as an internal control.
  • PCR reaction system 2 ⁇ l of 10 ⁇ Buffer was added to each reaction tube, and 2 ⁇ l of dNTP, 1 ⁇ l of forward primer, 1 ⁇ l of reverse primer, 1 ⁇ l of cDNA template, 0.2 ⁇ l of Taq enzyme, and water to 20 ⁇ l were added.
  • PCR reaction conditions were as follows: 94 ° C, 5 min pre-denaturation; 94 ° C, 30 sec denaturation; 55 ° C, 30 sec annealing; 72 ° C, 30 sec extension; 35 cycles, agarose gel electrophoresis detection of PCR amplification products, results
  • the circular RNA primer in Figure 1 is a reverse primer (black triangle symbol), while a pair of forward primers are designed as a control (white triangle symbol), and a set of gDNA template controls is established at RT-PCR to confirm that the circRNA is from Post-transcriptional cleavage, rather than mutations such as gene fusion, while detecting the linear gene GAPDH as a negative control.
  • the circ-NFATC3 divergent primer of Example 1 was used to amplify the circular RNA circ-NFATC3, and the hsaGAPDH convergent primer of Example 1 was used to amplify the internal reference gene.
  • the purpose of Ct is the Ct value of the target gene
  • the Ct housekeeper is the Ct value of the housekeeping gene.
  • ⁇ Ct Ct destination-Ct housekeeper, indicating the relative Ct value of the target gene of each sample relative to the housekeeping gene
  • 2- ⁇ Ct represents the treatment group.
  • the relative expression amount relative to the control group indicates the relative expression multiple of the target gene.
  • the results are shown in Figure 2.
  • RNaseR digestion confirmed that circ-NFATC3 is not sensitive to RNase.
  • RNaseR is an RNase that can digest linear RNA but has no effect on circular RNA.
  • the total RNA was digested with RNaseR and then subjected to QPCR. The results showed that the addition of RNaseR did not significantly affect the expression of circ-NFATC3, but the linear gene.
  • Example 3 Overexpression of circ-NFATC3 lentivirus and its stable cell line construction
  • Lipofectamine 2000 reagent was gently shaken, and 60 ⁇ l of Lipofectamine 2000 reagent was mixed with 1.5 ml of Opti-MEM in another tube, and incubated at room temperature for 5 minutes.
  • the DNA and Lipofectamine 2000 mixture was transferred to a culture medium of 293T cells, mixed, and cultured at 37 ° C in a 5% CO 2 cell incubator.
  • the medium containing the transfection mixture was aspirated, and 10 ml of a cell culture medium containing 10% serum was added to each flask, and the culture was continued for 48 hours at 37 ° C in a 5% CO 2 incubator.
  • the virus concentrate is in the filter cup.
  • the virus concentrate is removed, stored in a virus tube after packaging, and stored at 4 ° C for one week, or -80 ° C for long-term storage. Take one of them for viral biological titer determination.
  • Example 4 Determination of proliferation ability of liver cancer cells overexpressing circ-NFATC3 gene
  • MTS reagent was added at different time points (24h, 48h, 72h) at a ratio of 1:10, that is, 100 ⁇ l of the culture solution was added with 10 ⁇ l of the test solution.
  • Fig. 5 The results are shown in Fig. 5.
  • the growth rate of hepatoma cell line overexpressing circ-NFATC3 is slowed down, and the cell proliferation curve after overexpressing circ-NFATC3 gene in Huh7 cells is shown in Fig. 5.
  • the abscissa is the number of days and the ordinate is the enzyme standard.
  • the absorbance at 490 nm was measured by the instrument.
  • the results are shown in Fig. 6.
  • the migration rate of the liver cancer cell line overexpressing Circ-NFATC3 is increased, and the cell migration experiment results are specifically expressed after the circ-NFATC3 gene is overexpressed in the liver cancer cell Huh7, wherein the abscissa is the name of the treatment group and the ordinate is generated. The number of cells migrated.
  • Example 6 Cell invasion assay of hepatoma cells overexpressing circ-NFATC3 gene
  • Fig. 7 The results are shown in Fig. 7.
  • the invasive rate of hepatoma cell line overexpressing Circ-NFATC3 is increased, and the results of cell invasion assay after specific overexpression of circ-NFATC3 gene in Huh7 cells are shown, wherein the abscissa is the name of the treatment group and the ordinate is generated. The number of cells invading.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

提供了一种NFATC3基因的环状RNA circ-NFATC3及其用途，该环状RNA circ-NFATC3的核苷酸序列如SEQ IDNO:1所示，包含该环状RNA circ-NFATC3的药物组合物，以及一种包含能扩增该环状RNA circ-NFATC3的引物的肝癌诊断试剂盒。

Description

环状RNA circ-NFATC3及其用途 技术领域
本发明属于分子生物学和肿瘤学领域，具体涉及一种环状RNA circ-NFATC3及其用途。
背景技术
原发性肝细胞癌(Hepatocellular carcinoma，HCC，以下简称肝癌)是全球范围内最常见的恶性肿瘤之一。全球每年约有74万患者被新诊断为肝细胞癌，同时约有69万患者死于肝癌。其中我国占到了全球每年新发病例的55％，成为全世界肝癌最高发的地区之一。
迄今，以手术治疗为核心的综合治疗仍然是原发性肝癌患者获得长期生存的唯一希望，但是目前肝癌治疗状况存在早期诊断困难，手术根治率低、复发率高、预后差的困扰。主要原因之一是早期诊断困难，AFP作为唯一被广泛接受用于肝癌诊断或检测的血清学标记物，其诊断肝癌的敏感度只能达到约50％，众多因素最终导致超过70％的患者在首次就诊时便已进入肝癌晚期，从而丧失了包括手术切除或肝移植的外科根治性治疗的机会。故深入研究肝癌发生和发展中的分子机制、开发新的诊断标志物和治疗靶点成为当前肿瘤研究的热点和重点领域。
环状RNA(ciucular RNA，circRNA)是区别于传统线性RNA的RNA家族新成员，不具有5′末端帽子和3′末端poly(A)尾巴、并以共价键形成环形结构的非编码RNA分子。最新研究表明circRNA具有闭合环状结构，主要通过非典型可变剪切加工产生，广泛存在于各种生物细胞中，具有结构稳定，难以被RNA酶降解、表达丰度高、物种间保守性好，表达具有组织及时空特异性等特征，这些特点使得circRNA在新型疾病诊断与治疗方法的开发应用上具有广阔的前景。
Circ-NFATC3(CircBase ID：hsa_Circ_0000711)，其在基因组上的定位为： chr16：68155889-68160513，相应的线性基因为NFATC3(NM_173165)，环化序列有1298个碱基，包含NFATC3基因的第二和第三个外显子。申请人研究发现肝组织中NFATC3基因的RNA存在环化现象，且环状RNA circ-NFATC3在肝癌组织中表达量显著下调，过表达circ-NFATC3抑制肝癌细胞的增殖、迁移、侵袭，提示circ-NFATC3可能成为肝癌诊断和治疗的新途径。
发明内容
本发明的目的在于根据发明人对环状RNA circ-NFATC3在人肝癌中的表达及其对肝癌细胞生物学功能的调节作用的研究，提供基于circ-NFATC3基因及其表达产物在肝癌的诊断和治疗方面的用途。
为实现上述目的，本发明所采取的技术方案为：一种环状RNA circ-NFATC3，所述环状RNA circ-NFATC3的基因的核苷酸序列如SEQ ID NO：1所示。所述环状RNA circ-NFATC3的结构是由如SEQ ID NO：1所示的核苷酸序列转录后经剪接形成的首尾相连的环状RNA结构。
本发明还提供了一种药物组合物，所述药物组合物包含上述环状RNAcirc-NFATC3。
本发明还提供了一种肝癌诊断试剂盒，所述试剂盒包含能够扩增如上所述的环状RNA circ-NFATC3的引物。
优选地，所述扩增引物为由如SEQ ID NO：2和SEQ ID NO：3所示的DNA序列组成的引物对或由如SEQ ID NO：4和SEQ ID NO：5所示的DNA序列组成的引物对。
本发明还提供了上述所述的环状RNA circ-NFATC3在制备治疗肝癌的药物中的用途。
本发明还提供了circ-NFATC3基因作为靶基因在制备治疗肝癌的药物中的用途，所述circ-NFATC3基因的核苷酸序列如SEQ ID NO：1所示。
与现有技术相比，本发明的有益效果在于：
(1)本发明首先通过设计特异的环状RNA引物进行RT-PCR、一代测序、RNA酶降解实验证实circ-NFATC3基因的客观存在；
(2)本发明通过检测肝癌病人中circ-NFATC3基因表达情况，发现其表达水平明显降低，因此，可作为肝癌的诊断标志；
(3)本发明对circ-NFATC3基因进行了体外细胞功能学的研究，通过将circ-NFATC3基因序列构建到LVminiCirc慢病毒载体上，以构建过表达circ-NFATC3基因的Huh7稳定肝癌细胞系。过表达circ-NFATC3基因的肝癌细胞与转染空载体的对照肝癌细胞相比，其增殖速度、细胞迁移率及细胞侵袭能力等均显著降低。circ-NFATC3基因及其表达产物可以应用在制备治疗肝癌的药物中。
circ-NFATC3基因及其表达产物作为诊断肝癌的标志物，使肝癌诊断更加准确、快速，作为制备治疗肝癌药物的靶基因为治疗肝癌提供了新的治疗靶点和治疗途径。
附图说明
图1为本发明实施例1中circ-NFATC3基因表达产物的琼脂糖凝胶电泳图；
图2为反映本发明实施例2中RNaseR对circ-NFATC3和GAPDH影响情况的柱状图。
图3为本发明实施例2中QPCR检测肝癌组织中circ-NFATC3表达结果对比图；
图4为本发明实施例3中构建好的稳定细胞株荧光显微镜图和表达结果图；
图5为本发明实施例4中在肝癌细胞Huh7中特异性过表达circ-NFATC3基因后的细胞增殖曲线示意图，其中横坐标为天数，纵坐标为酶标仪检测的490nm吸光值；
图6为本发明实施例5中在肝癌细胞Huh7中特异过表达circ-NFATC3基因后的细胞迁移实验结果示意图，其中横坐标为处理组名称，纵坐标为发生迁移的细胞数目。
图7为本发明实施例6中在肝癌细胞Huh7中特异过表达circ-NFATC3基因后的细胞侵袭实验结果示意图，其中横坐标为处理组名称，纵坐标为发生侵袭的细胞数目。
具体实施方式
本发明首先通过设计能扩增环状RNA的特异性引物，PCR扩增出来NFATC3基因的环状RNA，接着进行RNaseR降解实验，确定了NFATC3基因表达一种由1298个核苷酸组成的，具有闭合环状结构的环状RNA分子。
进一步，本发明通过采用荧光定量PCR的方法检测circ-NFATC3基因在肝癌样本中的表达差异，结果显示circ-NFATC3基因在肝癌组织中的表达水平明显低于癌旁组织中的表达水平。故可制作检测该基因表达变化的试剂盒以用于诊断肝癌。
接着，我们对circ-NFATC3基因进行了体外细胞功能学的研究，通过将可以过表达circ-NFATC3基因序列的特异载体转染到Huh7肝癌细胞系，以建立该基因表达上调的细胞株。过表达circ-NFATC3基因的肝癌细胞与转染空载体的对照肝癌细胞相比，其增殖速度、细胞迁移率及细胞侵袭能力等均显著降低。因此，circ-NFATC3基因及其表达产物可以应用在制备治疗肝癌的药物中。
本发明所涉及的技术均为分子克隆常规技术手段，其中涉及的酶、引物、试剂以及反应条件在未作说明的情况下均可根据本领域技术人员的经验进行合理选择，其中涉及试剂耗材属于市售的普通产品，其中涉及的检测手段以及仪器也均为本领域技术人员所熟知并熟练掌握。
下面通过实施例和试验例对本发明的技术方案做进一步的说明，但不应理解为对本发明的限制。
实施例1：RT-PCR反应检测circ-NFATC3基因在肝癌组织中的表达。
具体实验方案如下：
1.RNA提取
1)组织处理：取10mg左右组织加入1mlTrizol，用匀浆机匀浆；离心15分钟，12000g，取上清。
2)向上清中加入200ul氯仿，上下用力颠倒混匀半分钟，静置3分钟。
3)4℃，12000g离心15分钟，此时可见裂解液分三层：上层为水相的RNA； 中层为DNA，脂类等；下层为细胞残渣，蛋白，多糖等。
4)取上清到新的EP管内；加入等体积的异丙醇，混匀，静置10分钟后，4℃，12000g离心10分钟。
5)小心去掉上清，注意不要丢失RNA沉淀，加入1ml 75％乙醇，上下颠倒，使沉淀块重悬起。
6)4℃，12000g离心10分钟，小心去掉上清，尽量吸干管壁的液体，注意不要丢失RNA沉淀，若沉淀松动可再次离心。晾干约15分钟，至管壁无液体。
7)加入适量体积(20-30ul)的DEPC水溶解RNA，58℃水浴10分钟。
8)取出2ul定量，测量buffer：10mM TrisCl(pH7.8)，根据定量结果进行逆转录。(1A260＝40μg/ml，A260/A280＝1.8～2.1)。
2.cDNA逆转录
1)实验体系
M-MLV Reverse Transcriptase：
Figure PCTCN2017087834-appb-000001
3.引物：环状RNA引物为反向引物，同时设计一对正向引物做对照，RT-PCR时设立一组gDNA模板对照，证实circRNA来自转录后剪切，而不是基因融合等突变。同时检测线性基因GAPDH作为阴性对照。使用的引物如下所列：
SEQ ID NO：2 Circ-NFATC3_F divergent GTGACTTTGGAGCTGAAACGATGG
SEQ ID NO：3 Circ-NFATC3_R divergent AAGGTAGCCGAGGGGCAGTAA
SEQ ID NO：4 Circ-NFATC3_F convergent CCATCGTTTCAGCTCCAAAGTCAC
SEQ ID NO：5 Circ-NFATC3_R convergent TTACTGCCCCTCGGCTACCTT
SEQ ID NO：6 hsaGAPDH convergent_F GAGTCAACGGATTTGGTCGT
SEQ ID NO：7 hsaGAPDH convergent_R GACAAGCTTCCCGTTCTCAG
SEQ ID NO：8 hsaGAPDH divergent_F TCCTCACAGTTGCCATGTAGACCC
SEQ ID NO：9 hsaGAPDH divergent_R TGCGGGCTCAATTTATAGAAACCGGG
4.PCR：以GAPDH作为内对照。PCR的反应体系：每个反应管中分别加入2μl 10×Buffer，分别加入2μl dNTP，1μl正向引物，1μl反向引物，1μl cDNA模板，0.2μl Taq酶，加水至20μl。PCR反应条件如下：94℃，5分钟预变性；94℃，30秒变性；55℃，30秒退火；72℃，30秒延伸；35个循环，琼脂糖凝胶电泳检测PCR扩增产物，结果见图1，图1中环状RNA引物为反向引物(黑色三角形符号)，同时设计一对正向引物做对照(白色三角形符号)，RT-PCR时设立一组gDNA模板对照，证实circRNA来自转录后剪切，而不是基因融合等突变，同时检测线性基因GAPDH作为阴性对照。
实施例2：QPCR检测肝癌中circ-NFATC3的表达情况
1.RNA提取：同实施例1；
2.cDNA逆转录：同实施例1；
3.QPCR扩增实验
1)实验体系：
Figure PCTCN2017087834-appb-000002
选用实施例1的circ-NFATC3 divergent引物用于扩增环状RNA circ-NFATC3，实施例1的hsaGAPDH convergent引物用于扩增内参基因。
2)反应条件：
第一步：95℃ 2min
第二步(40个循环)：95℃ 3秒，60℃ 30秒
第三步60-95℃溶解曲线
3)上机进行目标基因扩增
4)qPCR相对定量结果
目标基因的相对表达量计算公式为：2-ΔΔCt＝2-【(ΔCt)Test-(ΔCt)Control】。Ct目的为目标基因Ct值，Ct管家为管家基因Ct值。ΔCt＝Ct目的-Ct管家，表示各样本目的基因相对管家基因的相对Ct值，ΔΔCt＝(ΔCt)Test-(ΔCt)Control，表示处理组相对对照组进行归一化，2-ΔΔCt表示处理组相对对照组的相对表达量，表示目标基因相对表达倍数。
Total RNA按3U/ug的比例加入RNaseR进行消化，QPCR检测加与不加RNaseR对circ-NFATC3和GAPDH的影响，结果见图2，RNaseR消化证实circ-NFATC3对RNA酶不敏感。RNaseR是一个能消化线性RNA，但对环状RNA没有影响的RNA酶，将total RNA用RNaseR消化后再进行QPCR检测，结果显示加与不加RNaseR对circ-NFATC3表达没有明显影响，但是线性基因GAPDH经RNaseR消化后表达显著降低。
QPCR检测肝癌和相应癌旁组织中circ-NFATC3和GAPDH的表达水平，结果见图3，在24对肝癌临床组织样本中检测circ-NFATC3的表达，结果显示circ-NFATC3在癌组织中显著下调。Control：癌旁组织，Tumor：肝癌组织。
实施例3：过表达circ-NFATC3慢病毒及其稳定细胞系构建
1.过表达circ-NFATC3慢病毒载体构建：在上海捷瑞公司合成circ-NFATC3线性全序列，序列经过退火成双链DNA片段，通过多克隆位点插入到LVminiCirc载体，重组质粒通过测序进行鉴定，Control阴性对照为未插入序列的LVminiCirc空载体。
2.慢病毒包装
(1)转染前24h，用胰酶消化对数生长期的293T细胞，传代到10cm细胞培养皿，37℃、5％CO2培养箱内培养。24h待细胞密度达70％～80％时即可用于转染。细胞状态对于病毒包装至关重要，因此需要保证良好的细胞状态和较少的传代次数。
(2)转染前将细胞培养基更换为无血清培养基。
(3)向一灭菌离心管中加入所制备的各DNA溶液(LVminiCirc-Circ-NFATC3/LVminiCirc载体10μg，pGag/Pol载体5μg、pRev载体5μg、pVSV-G载体5μg)，与相应体积的Opti-MEM混合均匀，调整总体积为1.5ml。
(4)将Lipofectamine 2000试剂轻柔摇匀，取60μl Lipofectamine 2000试剂在另一管中与1.5ml Opti-MEM混合，在室温下温育5分钟。
(5)把稀释后的DNA与稀释后的Lipofectamine 2000进行混合，轻轻地颠倒混匀，不要振荡。
(6)混合后，在室温下温育20分钟，以便形成DNA与Lipofectamine 2000稀释液的转染复合物。
(7)将DNA与Lipofectamine 2000混合液转移至293T细胞的培养液中，混匀，于37℃，5％CO2细胞培养箱中培养。
(8)培养6小时后吸去含有转染混和物的培养基，每瓶细胞中加入含10％血清的细胞培养基10ml，于37℃、5％CO2培养箱内继续培养48小时。
3.病毒的收获及浓缩
(1)收集转染后48小时和72小时(转染即可为0小时计起)的293T细胞上清液。
(2)于4℃，4000g离心10min，除去细胞碎片。
(3)以0.45μm滤器过滤上清液于50ml离心管中。
(4)把病毒粗提液样品加入到过滤杯中(最多19ml)，盖上盖子。将过滤杯插到滤过液收集管中。
(5)组合好后，做好平衡，放在转头上。
(6)在5000×g离心，至需要的病毒浓缩体积。通常需要的时间为10-15分钟。
(7)离心结束后，过滤杯中的即为病毒浓缩液。
(8)将病毒浓缩液移出，分装后保存在病毒管中，可在4℃保存一周，或-80℃长期保存。取其中一支进行病毒生物学滴度测定。
4.慢病毒感染细胞：
(1)根据细胞的量将细胞在1.5ml管中离心收集然后用100-200ul的无血清 培养液稀释细胞沉淀，以细胞完全浸没在培养基中为准。
(2)吸取过表达的circ-NFATC3病毒液加入细胞中，将1.5ml管放在37℃度培养箱中孵育30分钟。另取LVminiCirc空载体对照病毒感染做对照细胞系。
(3)将管中混合溶液吸出加到培养皿中或孔里。
(4)加入足够量的新鲜培养液。
(5)12小时后换液。
(6)48小时后加入2ug/ml puromycin进行稳定细胞株筛选。
5.稳定细胞株鉴定：构建好的稳定细胞株荧光显微镜下拍照观察，GFP阳性率＞95％，同时收取部分细胞QPCR检测，证实circ-NFATC3的过表达效率＞2倍。结果见图4，将circ-NFATC3基因特异的序列构建到LVminiCirc慢病毒载体上，通过慢病毒构建过表达circ-NFATC3的Huh7-circ-NFATC3稳定细胞株，结果显示GFP阳性率＞95％，QPCR检测证实circ-NFATC3成功过表达，过表达效果达到2倍。
实施例4：过表达circ-NFATC3基因的肝癌细胞增殖能力测定
(1)将Huh7-circ-NFATC3细胞株及对照细胞消化成单细胞悬液，计数，调整细胞浓度为1×105个/ml，分到96孔板，每孔100ul，即每孔细胞为1×104个，各9孔。
(2)分别在不同的时间点(24h、48h、72h)加入MTS试剂，比例为1∶10，即100μl培养液加入10μl检测液。
(3)37℃孵育4h后，酶标仪检测490nm吸光值。
结果见图5，过表达circ-NFATC3的肝癌细胞株生长速度减慢，在肝癌细胞Huh7中特异性过表达circ-NFATC3基因后的细胞增殖曲线示意图，其中横坐标为天数，纵坐标为酶标仪检测的490nm吸光值。
实施例5过表达circ-NFATC3基因的肝癌细胞迁移能力检测
(1)胰酶消化成单细胞悬液，计数，用无血清培养基调整细胞浓度至1×106/ml。
(2)加入100μl细胞悬液至小室上室，在下室中加入600μl含不同浓度胎牛血清的完全培养基。37℃、5％CO2培养箱中孵育24h。
(3)取出小室，用棉签擦去上室的细胞，4％多聚甲醛固定10min，PBS洗涤一次，结晶紫染色10min，PBS洗涤一次，显微镜观测并拍照。
结果见图6，过表达Circ-NFATC3的肝癌细胞株迁移率增加，在肝癌细胞Huh7中特异过表达circ-NFATC3基因后的细胞迁移实验结果示意图，其中横坐标为处理组名称，纵坐标为发生迁移的细胞数目。
实施例6：过表达circ-NFATC3基因的肝癌细胞细胞侵袭实验
(1)将Matrigel置于4℃中过夜溶解，用预冷的基础培养基按Matrigel∶培养基＝1∶3的比例稀释，取40μl加入预冷的Transwell小室中，动作要慢，避免产生气泡。
(2)37℃孵育2小时使Matrigel凝固。
(3)分别在上下室加入100μl和600μl基础培养基，37℃水合过夜。次日吸去培养基。
(4)实验细胞胰酶消化后，取适量细胞悬液，800rpm离心5分钟。
(5)吸去上清，用基础培养基重悬细胞后，细胞计数并用基础培养基调整细胞浓度至1×106/ml，取100μl加入至Transwell小室上室，在下室加入600μl完全培养基。
(6)放入培养箱中培养24、48小时后，取出小室，用棉签擦去上室的细胞，4％多聚甲醛固定15分钟，PBS洗涤一次，1％结晶紫染色10分钟，PBS洗涤一次，显微镜下观察细胞是否穿过小孔。如有穿过，终止其他实验组，拍照并统计穿过的细胞数。
结果见图7，过表达Circ-NFATC3的肝癌细胞株侵袭率增加，在肝癌细胞Huh7中特异过表达circ-NFATC3基因后的细胞侵袭实验结果示意图，其中横坐标为处理组名称，纵坐标为发生侵袭的细胞数目。
最后所应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。

Claims (6)

  1. 一种环状RNA circ-NFATC3，其特征在于，所述环状RNA circ-NFATC3的基因的核苷酸序列如SEQ ID NO：1所示。
  2. 一种药物组合物，其特征在于，所述药物组合物包含如权利要求1所述的环状RNA circ-NFATC3。
  3. 一种肝癌诊断试剂盒，其特征在于，所述试剂盒包含能够扩增如权利要求1所述的环状RNA circ-NFATC3的引物。
  4. 根据权利要求3所述的肝癌诊断试剂盒，其特征在于，所述扩增引物为由如SEQ ID NO：2和SEQ ID NO：3所示的DNA序列组成的引物对或由如SEQ ID NO：4和SEQ ID NO：5所示的DNA序列组成的引物对。
  5. 如权利要求1所述的环状RNA circ-NFATC3在制备治疗肝癌的药物中的用途。
  6. circ-NFATC3基因作为靶基因在制备治疗肝癌的药物中的用途，其特征在于，所述circ-NFATC3基因的核苷酸序列如SEQ ID NO：1所示。
PCT/CN2017/087834 2016-08-05 2017-06-10 环状RNA circ-NFATC3及其用途 WO2018024034A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610640334.4 2016-08-05
CN201610640334.4A CN106191067B (zh) 2016-08-05 2016-08-05 环状RNA circ-NFATC3及其用途

Publications (1)

Publication Number Publication Date
WO2018024034A1 true WO2018024034A1 (zh) 2018-02-08

Family

ID=57514413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/087834 WO2018024034A1 (zh) 2016-08-05 2017-06-10 环状RNA circ-NFATC3及其用途

Country Status (2)

Country Link
CN (1) CN106191067B (zh)
WO (1) WO2018024034A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111057764A (zh) * 2019-12-25 2020-04-24 广东省微生物研究所（广东省微生物分析检测中心） CircRNA PVT1及肽段在肿瘤生长预测、转移预测、预后评估和治疗中的应用
CN111778334A (zh) * 2020-07-13 2020-10-16 中山大学孙逸仙纪念医院 一种CircRNA作为肝癌肿瘤标志物的评价方法
CN112458170A (zh) * 2020-11-26 2021-03-09 南方医科大学珠江医院 用于检测circCSPP1靶标的检测试剂及应用
CN113278698A (zh) * 2021-05-27 2021-08-20 清远市人民医院 环状RNAcirc0001610及其表达产物在诊断和治疗膀胱癌药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191067B (zh) * 2016-08-05 2019-10-01 广州永诺生物科技有限公司 环状RNA circ-NFATC3及其用途
CN106834290B (zh) * 2017-01-23 2020-05-22 中山大学附属肿瘤医院 一种环状rna及其用途
CN109468320A (zh) * 2018-11-13 2019-03-15 复旦大学附属中山医院 一种环状rna及其在肝癌诊断中的应用
CN113122638B (zh) * 2021-03-15 2023-08-25 内蒙古医科大学 一种hsa-novel_circ_0006787分子在肝癌治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191067A (zh) * 2016-08-05 2016-12-07 广州永诺生物科技有限公司 环状RNA circ‑NFATC3及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105176981B (zh) * 2015-09-17 2017-03-15 广州永诺健康科技有限公司 用于环状rna表达的dna序列和表达载体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191067A (zh) * 2016-08-05 2016-12-07 广州永诺生物科技有限公司 环状RNA circ‑NFATC3及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MEMCZAK, S. ET AL.: "Circular RNAs Are A Large Class of Animal RNAs with Regulatory Potency", NATURE, vol. 495, 27 February 2013 (2013-02-27), pages 333 - 338, XP055103972, ISSN: 0028-0836 *
YIN, YATAO ET AL.: "Process of Nuclear Factor of Activated T Cells in Clinical Research", J OURNAL OF MEDICAL POSTGRADUATES, vol. 24, no. 1, 8 January 2011 (2011-01-08), pages 109 - 112, ISSN: 1008-8199 *
ZHANG, JIN ET AL.: "Differential Expression of Nuclear Factor of Activated T Cell Gene Family Member mRNA in Hepatocellular Carcinoma Tissues and Adjacent Non-tumorous Tissues", CHINESE JOURNAL OF EXPERIMENTAL SURGERY, vol. 29, no. 2, 24 February 2012 (2012-02-24), pages 237 - 239, ISSN: 1001-9030 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111057764A (zh) * 2019-12-25 2020-04-24 广东省微生物研究所（广东省微生物分析检测中心） CircRNA PVT1及肽段在肿瘤生长预测、转移预测、预后评估和治疗中的应用
CN111778334A (zh) * 2020-07-13 2020-10-16 中山大学孙逸仙纪念医院 一种CircRNA作为肝癌肿瘤标志物的评价方法
CN112458170A (zh) * 2020-11-26 2021-03-09 南方医科大学珠江医院 用于检测circCSPP1靶标的检测试剂及应用
CN113278698A (zh) * 2021-05-27 2021-08-20 清远市人民医院 环状RNAcirc0001610及其表达产物在诊断和治疗膀胱癌药物中的应用
CN113278698B (zh) * 2021-05-27 2022-12-27 清远市人民医院 环状RNAcirc0001610及其表达产物在诊断和治疗膀胱癌药物中的应用

Also Published As

Publication number Publication date
CN106191067B (zh) 2019-10-01
CN106191067A (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
WO2018024034A1 (zh) 环状RNA circ-NFATC3及其用途
WO2018024033A1 (zh) 环状RNA circ-CCNY及其用途
CN106834290B (zh) 一种环状rna及其用途
CN107663539B (zh) 环状RNA circ-PTGR1的用途
CN105524924B (zh) 环状RNA circ‑ZKSCAN1的用途
CN107760784B (zh) 环状RNA circ-FOXP1的用途
CN110384800B (zh) LncRNA XLOC_075168在制备促进血管新生的药物中的应用
CN107828888B (zh) 环状RNA circ-PTPRA的用途
CN113278698B (zh) 环状RNAcirc0001610及其表达产物在诊断和治疗膀胱癌药物中的应用
CN108660212B (zh) Wdr1基因在制备非小细胞肺癌治疗和检测产品中的应用
CN111172290B (zh) 肝细胞癌诊断和治疗的miRNA
CN114517204B (zh) 一种用于肿瘤治疗靶点和诊断生物标志物的circPOLK及其应用
CN114934048B (zh) 一种用于肿瘤治疗靶点和诊断生物标志物的circMTMR14及试剂盒和应用
CN112813166B (zh) 一种前列腺癌标志物及其治疗药物
CN112410429B (zh) Fxyd3作为胃癌诊断标志物和治疗靶标的应用
CN107184983B (zh) 一种肺腺癌的诊治靶标
CN111471682A (zh) miR-23a作为诊断和治疗胃癌伪管生成标志物的应用
CN106729751B (zh) 一种microRNA分子用于检测和治疗乳腺癌的用途
CN110652522B (zh) miR-2052在制备抗肝癌药物中的应用
CN114002431B (zh) Tnnt1在制备病毒型肝细胞癌诊断试剂盒及制备或筛选抗肝癌药物中的应用
CN111763735B (zh) 肿瘤差异表达基因及其应用
CN113186224B (zh) 具有抑制乙肝病毒复制活性的microRNA-27a及其应用
CN113699234B (zh) 长链非编码RNA Linc01605在作为胃癌诊断性试剂盒及靶向药物开发中的应用
CN113122638B (zh) 一种hsa-novel_circ_0006787分子在肝癌治疗中的应用
CN113789340B (zh) 环状RNA hsa_circ_0001741的表达载体、重组工程菌及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17836217

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17836217

Country of ref document: EP

Kind code of ref document: A1